General Information of Drug (ID: DMZT89C)

Drug Name
DNL151 Drug Info
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMZT89C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DNL201 DMFEORD Parkinson disease 8A00.0 Phase 1 [1]
BIIB094 DMLUO5K Parkinson disease 8A00.0 Phase 1 [2]
Pyrrolo-pyridine derivative 2 DMVNY5I N. A. N. A. Patented [3]
Bidentate ligands of Markush derivative 2 DM2QNMC N. A. N. A. Patented [3]
Oxindole derivative 3 DM0ENF3 N. A. N. A. Patented [3]
Aminopyridine derivative 3 DMSLJE8 N. A. N. A. Patented [3]
Fused thiophene derivative 1 DMV7IX4 N. A. N. A. Patented [3]
Oxindole derivative 4 DM3U58I N. A. N. A. Patented [3]
Bidentate ligands of Markush derivative 1 DMB08D3 N. A. N. A. Patented [3]
Pyrrolo-pyrimidine derivative 8 DMZH27I N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leucine-rich repeat kinase 2 (LRRK2) TTK0FEA LRRK2_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Ionis
3 Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.